Ruxolitinib treatment in a STAT1 GOF patient with T1D and concomitant autoimmune manifestations resulted in reduced insulin dependence, with eventual discontinuation of insulin therapy (4). This evidence concerns the gene INS and type 1 diabetes mellitus.